Rituximab for Treatment of Hemophilia A with High-Responder Inhibitors

نویسندگان
Toogeh , Gholamreza ID 1
Faranoush , Mohammad ID 2
Karimi , Katayoun ID 3
Managhchi , Mohammad-Reza ID 4
Zarrabi , Fariba ID 5
Rezaiei–Hemami , Mohsen ID 6
Roushan , Nader ID 7

1 Thrombosis Hemostasis Research Center, Tehran University of Medical Sciences, Tehran, Iran

2 Pediatric Growth and development research center , Endocrinology Institute, Iran university of medical sciences, Tehran Iran

3 Thrombosis Hemostasis Research Center, Tehran University of Medical Sciences, Tehran, Iran

4 Thrombosis Hemostasis Research Center, Tehran University of Medical Sciences, Tehran, Iran

5 Thrombosis Hemostasis Research Center, Tehran University of Medical Sciences, Tehran, Iran

6 Rasool Akram Hospital , Iran university of medical sciences, Tehran Iran

7 Gastroenterology Department, Imam Khomeini Hospital ,Tehran University of Medical Sciences ,Tehran, Iran.

doi
چکیده

Background: The development of inhibitors is a complication factor replacement therapy in hereditary factor VIII deficiency. Several management options are available for the treatment of inhibitor. Rituximab, a monoclonal antibody against CD20, reduces inhibitor level in rare bleeding disorders. The aim of this study was to evaluate the effectiveness of rituximab in ...

کلیدواژه‌ها
Hemophilia A, Rituximab, Inhibitor, High responder, Therapeutics, CD20 antibody